Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
/
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.
Qlife Holding AB is an innovative healthcare technology company focused on providing advanced diagnostic solutions. Its primary function is to develop and deliver easy-to-use, portable clinical biomarker testing systems designed for both professional healthcare settings and personal use. With a strong emphasis on improving healthcare access and precision, Qlife Holding AB's technology enables users to perform laboratory-quality tests conveniently outside of traditional healthcare environments. This capability is significant for chronic disease management and early diagnosis, empowering individuals and clinicians to monitor health conditions more effectively. Qlife operates within the global healthcare sector, impacting the way diagnostics are integrated into daily health management. By leveraging cutting-edge biotechnology and digital platforms, the company plays a crucial role in the growing trend towards personalized medicine and decentralized healthcare. Qlife’s contributions aid in expanding the availability and efficiency of medical testing, which is pivotal in enhancing patient outcomes and optimizing healthcare costs in various medical fields.
kr 0.17
+kr 0.00 (+2.23%)
EOD Jun 25, 2026 · Twelve Data
The business is unprofitable at the operating level (-5982.72% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 548.0% YoY with margins expanding 19873.3pp.
ROIC dropped from -70.57% to -132.36%, capital efficiency is deteriorating. Negative free cash flow of -kr 21M. The business is consuming cash, not generating it.
Based on TTM earnings · Diluted shares
Profitability & Returns
Revenue (TTM)
kr 239K
▲ +548.0% YoY
Net Income (TTM)
-kr 21M
▲ +63.2% YoY
Op. Margin
-8236.82%
▲ +19873.3pp YoY
ROIC
-132.36%
▼ -61.8pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-kr 13M
▲ +61.6% YoY
Op. Cash Flow (TTM)
-kr 12M
▲ +54.5% YoY
Net Debt
kr 13M
Cash & Equiv.
kr 1M
3Y CAGR: -73.8%
Continue Research
Qlife Holding AB (QLIFE.XSTO)'s valuation is best read against its own history, its peers, and the growth its price implies. A high multiple is not the same as overvalued: fast-growing, high-quality businesses can deserve a premium. See the general approach in how to tell if a stock is overvalued.
On quality, Qlife Holding AB scores 0/100 on Intrinsiqq's quality scorecard (a lower-quality business on these measures), weighing growth, margins, returns on capital, share count, and balance-sheet strength. All figures are computed from SEC filings; read the full . This is analysis, not investment advice.
Qlife Holding AB scores 0 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which makes it a lower-quality business on these measures. Recent fundamentals include a -8,236.8% operating margin and a -132.4% return on invested capital. The score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, share-count change, and balance-sheet strength, all computed from SEC filings, not opinion. Because valuation only means something relative to quality, the full metric-by-metric breakdown is on the quality scorecard.
That depends on valuation and quality together, not either alone. you should weigh QLIFE.XSTO's valuation and scores 0/100 on quality (lower-quality). A cheap price is only a bargain if the business is durable, and a premium can be justified by genuine quality, so the two questions, "is it cheap?" and "is it good?", only make sense side by side. Read the valuation against the quality scorecard, run the DCF on your own assumptions, and decide for yourself. This is analysis from SEC filings, not investment advice.